Condition
Cancer, Gastric
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed2
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06391749Enrolling By Invitation
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
NCT05227261Completed
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
NCT03957031CompletedPrimary
Gastric Cancer Risk Factors Associated With EU and CELAC Populations
Showing all 3 trials